Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner

Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner

Robert M Taylor,1,2 Laurel O Sillerud1,31Department of Biochemistry and Molecular Biology, 2New Mexico Cancer Nanoscience and Microsystems Training Center, 3UNM Cancer Center, University of New Mexico, Albuquerque, NM, USABackground and methods: Problems with the clinical management of prostate canc...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Taylor RM, Sillerud LO
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/45e5081921bd476e9ea08803c812a28b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:45e5081921bd476e9ea08803c812a28b
record_format dspace
spelling oai:doaj.org-article:45e5081921bd476e9ea08803c812a28b2021-12-02T01:13:36ZPaclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner1176-91141178-2013https://doaj.org/article/45e5081921bd476e9ea08803c812a28b2012-08-01T00:00:00Zhttp://www.dovepress.com/paclitaxel-loaded-iron-platinum-stealth-immunomicelles-are-potent-mri--a10620https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Robert M Taylor,1,2 Laurel O Sillerud1,31Department of Biochemistry and Molecular Biology, 2New Mexico Cancer Nanoscience and Microsystems Training Center, 3UNM Cancer Center, University of New Mexico, Albuquerque, NM, USABackground and methods: Problems with the clinical management of prostate cancer include the lack of both specific detection and efficient therapeutic intervention. We report the encapsulation of superparamagnetic iron platinum nanoparticles (SIPPs) and paclitaxel in a mixture of polyethyleneglycolated, fluorescent, and biotin-functionalized phospholipids to create multifunctional SIPP-PTX micelles (SPMs) that were conjugated to an antibody against prostate-specific membrane antigen (PSMA) for the specific targeting, magnetic resonance imaging (MRI), and treatment of human prostate cancer xenografts in mice.Results: SPMs were 45.4 ± 24.9 nm in diameter and composed of 160.7 ± 22.9 µg/mL iron, 247.0 ± 33.4 µg/mL platinum, and 702.6 ± 206.0 µg/mL paclitaxel. Drug release measurements showed that, at 37°C, half of the paclitaxel was released in 30.2 hours in serum and two times faster in saline. Binding assays suggested that PSMA-targeted SPMs specifically bound to C4-2 human prostate cancer cells in vitro and released paclitaxel into the cells. In vitro, paclitaxel was 2.2 and 1.6 times more cytotoxic than SPMs to C4-2 cells at 24 and 48 hours of incubation, respectively. After 72 hours of incubation, paclitaxel and SPMs were equally cytotoxic. SPMs had MRI transverse relaxivities of 389 ± 15.5 Hz/mM iron, and SIPP micelles with and without drug caused MRI contrast enhancement in vivo.Conclusion: Only PSMA-targeted SPMs and paclitaxel significantly prevented growth of C4-2 prostate cancer xenografts in nude mice. Furthermore, mice injected with PSMA-targeted SPMs showed significantly more paclitaxel and platinum in tumors, compared with nontargeted SPM-injected and paclitaxel-injected mice.Keywords: iron platinum, MRI, prostate cancer, micelle, paclitaxelTaylor RMSillerud LODove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2012, Iss default, Pp 4341-4352 (2012)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Taylor RM
Sillerud LO
Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner
description Robert M Taylor,1,2 Laurel O Sillerud1,31Department of Biochemistry and Molecular Biology, 2New Mexico Cancer Nanoscience and Microsystems Training Center, 3UNM Cancer Center, University of New Mexico, Albuquerque, NM, USABackground and methods: Problems with the clinical management of prostate cancer include the lack of both specific detection and efficient therapeutic intervention. We report the encapsulation of superparamagnetic iron platinum nanoparticles (SIPPs) and paclitaxel in a mixture of polyethyleneglycolated, fluorescent, and biotin-functionalized phospholipids to create multifunctional SIPP-PTX micelles (SPMs) that were conjugated to an antibody against prostate-specific membrane antigen (PSMA) for the specific targeting, magnetic resonance imaging (MRI), and treatment of human prostate cancer xenografts in mice.Results: SPMs were 45.4 ± 24.9 nm in diameter and composed of 160.7 ± 22.9 µg/mL iron, 247.0 ± 33.4 µg/mL platinum, and 702.6 ± 206.0 µg/mL paclitaxel. Drug release measurements showed that, at 37°C, half of the paclitaxel was released in 30.2 hours in serum and two times faster in saline. Binding assays suggested that PSMA-targeted SPMs specifically bound to C4-2 human prostate cancer cells in vitro and released paclitaxel into the cells. In vitro, paclitaxel was 2.2 and 1.6 times more cytotoxic than SPMs to C4-2 cells at 24 and 48 hours of incubation, respectively. After 72 hours of incubation, paclitaxel and SPMs were equally cytotoxic. SPMs had MRI transverse relaxivities of 389 ± 15.5 Hz/mM iron, and SIPP micelles with and without drug caused MRI contrast enhancement in vivo.Conclusion: Only PSMA-targeted SPMs and paclitaxel significantly prevented growth of C4-2 prostate cancer xenografts in nude mice. Furthermore, mice injected with PSMA-targeted SPMs showed significantly more paclitaxel and platinum in tumors, compared with nontargeted SPM-injected and paclitaxel-injected mice.Keywords: iron platinum, MRI, prostate cancer, micelle, paclitaxel
format article
author Taylor RM
Sillerud LO
author_facet Taylor RM
Sillerud LO
author_sort Taylor RM
title Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner
title_short Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner
title_full Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner
title_fullStr Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner
title_full_unstemmed Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner
title_sort paclitaxel-loaded iron platinum stealth immunomicelles are potent mri imaging agents that prevent prostate cancer growth in a psma-dependent manner
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/45e5081921bd476e9ea08803c812a28b
work_keys_str_mv AT taylorrm paclitaxelloadedironplatinumstealthimmunomicellesarepotentmriimagingagentsthatpreventprostatecancergrowthinapsmadependentmanner
AT sillerudlo paclitaxelloadedironplatinumstealthimmunomicellesarepotentmriimagingagentsthatpreventprostatecancergrowthinapsmadependentmanner
_version_ 1718403195715190784

Ejemplares similares